NEW YORK (Reuters Health), Feb 6 - The results of a randomized trial indicate that sequential and alternating chemotherapy with radiotherapy provide similar survival and larynx preservation in patients with advanced squamous cell cancer of the larynx.
The EORTC trial 24954, reported in the Journal of the National Cancer Institute for February 4, included 450 patients with resectable cancer of the larynx or hypopharynx. In the sequential arm, patients received four cycles of cisplatin and 5-fluorouracil followed by radiotherapy. In the alternating arm, the four chemo cycles were interspersed with radiation therapy.
The former regimen involved 70 Gy of radiation, while the latter involved a total of 60 Gy.
During a median follow-up period of 6.5 years, no significant difference in survival rates with a functional larynx was noted between the study groups, lead author Dr. Jean Lefebvre, from Centre Oscar Lambret, Lille, France, and colleagues report. Likewise, median overall survival in the sequential and alternating chemotherapy groups was comparable (4.4 versus 5.1 years), as was the progression-free interval (3.0 versus 3.1 years).
The rates of grade 3 or 4 mucositis in the sequential and alternating chemotherapy groups were 32% and 21%, respectively. The corresponding rates of later severe edema, fibrosis, or both were 16% and 11%.
"We can conclude that findings from the EORTC trial 24954 are similar to those reported in 1996 that support induction therapy with cisplatin plus 5-fluorouracil as an alternative to laryngopharyngectomy for stage T2-T4, N0-N2 cancers arising in the hypopharynx," Dr. Arlene Forastiere and Dr. Andy Trotti, from Johns Hopkins University School of Medicine, Baltimore, write in a related editorial.
Still, the chemoradiotherapy regimens studied are far from perfect, the authors note, adding that "more effective and less toxic approaches are needed."
J Natl Cancer Inst 2009;101:129-131,142-152.
Last Updated: 2009-02-05 8:00:24 -0400 (Reuters Health)
Copyright © 2009 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.